1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceuticals in Norway

Pharmaceuticals in Norway

  • April 2014
  • -
  • MarketLine
  • -
  • 34 pages

Introduction

Pharmaceuticals in Norway industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2009-13, and forecast to 2018). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Norway pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2013 annual average exchange rates.

*The Norwegian pharmaceuticals market had total revenues of $2.1bn in 2013, representing a compound annual growth rate (CAGR) of 0.9% between 2009 and 2013.

*The performance of the market is forecast to accelerate, with an anticipated CAGR of 1.5% for the five-year period 2013 - 2018, which is expected to drive the market to a value of $2.2bn by the end of 2018.

*

Features

Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Norway

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Norway

Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Norway pharmaceuticals market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Norway economy

Key Questions Answered

What was the size of the Norway pharmaceuticals market by value in 2013?

What will be the size of the Norway pharmaceuticals market in 2018?

What factors are affecting the strength of competition in the Norway pharmaceuticals market?

How has the market performed over the last five years?

Who are the top competitiors in Norway's pharmaceuticals market?

Table Of Contents

Pharmaceuticals in Norway
TABLE OF CONTENTS

Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
AstraZeneca PLC 20
GlaxoSmithKline Plc 23
Pfizer Inc. 27
Macroeconomic Indicators 30
Country Data 30
Appendix 32
Methodology 32
Industry associations 33
Related MarketLine research 33

LIST OF TABLES

Table 1: Norway pharmaceuticals market value: $ billion, 2009-13 8
Table 2: Norway pharmaceuticals market geography segmentation: $ billion, 2013 9
Table 3: Norway pharmaceuticals market share: % share, by value, 2013 10
Table 4: Norway pharmaceuticals market value forecast: $ billion, 2013-18 11
Table 5: AstraZeneca PLC: key facts 20
Table 6: AstraZeneca PLC: key financials ($) 21
Table 7: AstraZeneca PLC: key financial ratios 21
Table 8: GlaxoSmithKline Plc: key facts 23
Table 9: GlaxoSmithKline Plc: key financials ($) 24
Table 10: GlaxoSmithKline Plc: key financials (£) 25
Table 11: GlaxoSmithKline Plc: key financial ratios 25
Table 12: Pfizer Inc.: key facts 27
Table 13: Pfizer Inc.: key financials ($) 28
Table 14: Pfizer Inc.: key financial ratios 28
Table 15: Norway size of population (million), 2009-13 30
Table 16: Norway gdp (constant 2000 prices, $ billion), 2009-13 30
Table 17: Norway gdp (current prices, $ billion), 2009-13 30
Table 18: Norway inflation, 2009-13 31
Table 19: Norway consumer price index (absolute), 2009-13 31
Table 20: Norway exchange rate, 2009-13 31

LIST OF FIGURES

Figure 1: Norway pharmaceuticals market value: $ billion, 2009-13 8
Figure 2: Norway pharmaceuticals market geography segmentation: % share, by value, 2013 9
Figure 3: Norway pharmaceuticals market share: % share, by value, 2013 10
Figure 4: Norway pharmaceuticals market value forecast: $ billion, 2013-18 11
Figure 5: Forces driving competition in the pharmaceuticals market in Norway, 2013 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Norway, 2013 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Norway, 2013 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Norway, 2013 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Norway, 2013 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Norway, 2013 19
Figure 11: AstraZeneca PLC: revenues and profitability 22
Figure 12: AstraZeneca PLC: assets and liabilities 22
Figure 13: GlaxoSmithKline Plc: revenues and profitability 25
Figure 14: GlaxoSmithKline Plc: assets and liabilities 26
Figure 15: Pfizer Inc.: revenues and profitability 29
Figure 16: Pfizer Inc.: assets and liabilities 29


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.